BSE Live
Nov 05, 16:00Prev. Close
0.77
Open Price
0.80
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.77 (38071)
NSE Live
Nov 05, 15:32Prev. Close
0.70
Open Price
0.65
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
| Profit & Loss account of Sterling Biotech (in Rs. Cr.) | Mar 18 | Mar 17 | Mar 16 | Dec 14 | Dec 13 | |
| 12 mths | 12 mths | 15 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 350.65 | 400.19 | 560.53 | 666.95 | 718.07 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 31.76 | 36.54 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 350.65 | 368.43 | 523.99 | 666.95 | 718.07 | |
| Total Operating Revenues | 350.65 | 368.43 | 523.99 | 666.95 | 718.07 | |
| Other Income | 7.14 | 3.98 | 7.85 | 3.68 | 4.26 | |
| Total Revenue | 357.79 | 372.40 | 531.84 | 670.63 | 722.33 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 237.83 | 258.61 | 444.37 | 617.84 | 484.35 | |
| Purchase Of Stock-In Trade | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 13.63 | 14.85 | -89.93 | -152.33 | 27.50 | |
| Employee Benefit Expenses | 58.41 | 54.41 | 66.11 | 51.67 | 54.68 | |
| Finance Costs | 439.67 | 369.80 | 414.78 | 469.51 | 437.71 | |
| Depreciation And Amortisation Expenses | 245.75 | 263.55 | 345.14 | 276.57 | 254.32 | |
| Other Expenses | 28.32 | 27.98 | 38.99 | 38.53 | 56.87 | |
| Total Expenses | 1,023.61 | 989.20 | 1,219.46 | 1,301.79 | 1,315.41 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | -665.82 | -616.80 | -687.62 | -631.16 | -593.08 | |
| Exceptional Items | -772.29 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | -1,438.12 | -616.80 | -687.62 | -631.16 | -593.08 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | -432.73 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 0.00 | -204.34 | -237.15 | -204.78 | -192.43 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | -432.73 | -204.34 | -237.15 | -204.78 | -192.43 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | -1,005.39 | -412.46 | -450.47 | -426.38 | -400.65 | |
| Profit/Loss From Continuing Operations | -1,005.39 | -412.46 | -450.47 | -457.71 | -400.65 | |
| Profit/Loss For The Period | -1,005.39 | -412.46 | -450.47 | -457.71 | -400.65 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | -36.94 | -15.15 | -16.55 | -16.82 | -14.96 | |
| Diluted EPS (Rs.) | -36.94 | -9.52 | -10.40 | -10.57 | -13.24 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Raw Materials | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
17.09.2024
Zydus Lifesciences board approves acquisition of API business of Sterling Biotech for Rs 84 crore
30.08.2022
Five promoters who siphoned funds overseas, defrauded Indian banks
29.09.2020
Court declares Sterling Biotech promoters 'fugitive economic offenders'
28.08.2019
Sterling Biotech case: ED records statement of Ahmed Patel's son Faisal
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth